SUBSCRIBE
SUBSCRIBE
BioCapital

Endocrinologic And Metabolic Drugs Advisory Committee Meeting

September 30, 2008 | 
1 min read

The committee will discuss the safety and efficacy of biologic license application (BLA) 125291, MYOZYME (algucosidase alfa) Genzyme Corporation, for the treatment of late onset Pompe disease.

Events
MORE ON THIS TOPIC
Medical characters fighting the epidemic flat vector concept operation hand drawn illustration
Obesity
Analysts Home In on Safety as Novo, Lilly, Amgen Highlight Weight Loss Data at ADA
June 27, 2025
 · 
5 min read
 · 
Heather McKenzie
IN PARTNERSHIP WITH PATSNAP
Webinar: Beyond Theory: Real-World AI Wins in Life Science R&D, Faster & Smarter
June 25, 2025
 · 
1 min read
 · 
BioSpace Insights
Pictured: (From L) Joe Ross, Camille Bedrosian, Emil Kakkis and Heather McKenzie
Rare diseases
FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent
June 24, 2025
 · 
3 min read
 · 
Heather McKenzie
From left to right: Jeff Quillen, Foley Hoag; Jim Cirenza, DNB Bank; Andrew Meadow, Health Innovation Capital; Greg Benning, Back Bay Life Science Advisors; Jonathan Gertler, Back Bay Life Science Advisors
Collaboration
Partner-Seeking Biotechs Find Plenty of Hands To Shake as BIO2025 Kicks Off
June 16, 2025
 · 
2 min read
 · 
Jef Akst